Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder

In brief

There is a high prevalence of smoking among people with schizophrenia, and there are few smoking treatment programs for these smokers. The aims of this study are to investigate the separate and combined effects of bupropion and a voucher incentive program on smoking in people with schizophrenia.

Key facts

Study ID

NCT00136760

Run by

Brown University

People needed

57

Starts

2003-09-01

Expected to finish

2009-03-01

Last updated by the study team

2015-10-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of schizophrenia or schizoaffective disorder, smoke 20-50 cpd, clinically stable on antipsychotic and antidepressant medications

You may not qualify if…

• Pregnant/nursing women, seizure disorder, lowered seizure threshold due to other medical conditions, positive urine drug screen positive breath alcohol test, past 2 weeks use of MAO inhibitors, any form of bupropion, cimetidine, phenobarbital, phenytoin, DA agonists, anorectics, stimulants

Where it is running

• Brown University — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.